You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東瑞製藥(02348.HK)2021年度歸母淨利潤升33.6%至3.58億元 末期息0.065港幣
格隆匯 03-27 19:51

格隆匯3月27日丨東瑞製藥(02348.HK)公佈,截至2021年12月31日止年度,實現收入11.65億元(人民幣,下同),同比增長13.8%;毛利6.81億元,同比增長23.7%;毛利率58.5%,較上年同期增加4.7個百分點,母公司擁有人應占淨利潤3.58億元,同比增長33.6%;基本每股盈利0.2392元,擬派每股末期股息0.065港幣。

母公司擁有人應占淨利潤含集團出售蘇州東瑞醫藥科技有限公司65%股權的投資收益9906.9萬元;東瑞(南通)醫藥科技有限公司處置資產損失2956.1萬元;投資於聯營公司康融東方(廣東)醫藥有限公司承擔的虧損4641.8萬元(2020年:1877.1萬元)。撇除以上因素,經營性溢利約3.35億元(2020年:2.87億元),較2020年上升16.8%。

收入與經營性溢利增加,主要由於集團在全國藥品集中採購(統稱“藥品集中採購”)分別中標的產品:苯磺酸氨氯地平片5毫克、阿託伐他汀鈣片10毫克、恩替卡韋分散片0.5毫克、鹽酸左西替利嗪片5毫克等專科藥物銷售放量,銷售量較2020年上升所致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account